Omicron SARS-CoV-2 variant of concern: A review on its transmissibility, immune evasion, reinfection, and severity
- PMID: 35583528
- PMCID: PMC9276130
- DOI: 10.1097/MD.0000000000029165
Omicron SARS-CoV-2 variant of concern: A review on its transmissibility, immune evasion, reinfection, and severity
Abstract
Omicron, the new Covid-19 variant, has already become dominant in many countries and is spreading at an unprecedented speed. The objective of this study was to review the existing literature on Omicron's transmissibility, immune evasion, reinfection, and severity.A literature search was performed using "PubMed," "Web of Science," "Scopus," "ScienceDirect," "Google Scholar," "medRxiv," and "bioRxiv." Data were extracted from articles that reported at least one of the following: transmissibility, immune evasion, reinfection, and severity related to Omicron.We found that Omicron spread faster than any other variant. This higher transmissibility can be ascribed to its extraordinary ability to evade the immunity developed by both vaccination and previous infections. However, we found that infections by Omicron were significantly less severe than those caused by Delta and other previous variants. We observed a significantly lower incidence of hospitalization, intensive care unit admission, and mechanical ventilator use in Omicron infections than in Delta or other variants. A substantially shorter median hospital stay and lower fatality rate were also observed in the Omicron infections. Despite Omicron's higher potential to evade immunity, vaccines and booster shots were found to be still significantly effective in protecting against severe Covid-19 infections.Omicrons may be less severe than other variants of concern. However, its immune evasiveness and rapid spread pose an enormous threat to the global healthcare system.
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors have no funding and conflicts of interests to disclose.
Similar articles
-
Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.BMC Infect Dis. 2023 Jun 26;23(1):432. doi: 10.1186/s12879-023-08328-3. BMC Infect Dis. 2023. PMID: 37365490 Free PMC article.
-
Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review.Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8019-8022. doi: 10.26355/eurrev_202112_27653. Eur Rev Med Pharmacol Sci. 2021. PMID: 34982466 Review.
-
Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron.Nature. 2025 Mar;639(8056):1024-1031. doi: 10.1038/s41586-024-08511-9. Epub 2025 Feb 5. Nature. 2025. PMID: 39910292 Free PMC article.
-
SARS-CoV-2 immune response and reinfection in vaccinated Maya and mestizo in Southeast of Mexico.Salud Publica Mex. 2023 Dec 8;66(1, ene-feb):14-16. doi: 10.21149/15186. Salud Publica Mex. 2023. PMID: 38065105
-
Reduction in the infection fatality rate of Omicron variant compared with previous variants in South Africa.Int J Infect Dis. 2022 Jul;120:146-149. doi: 10.1016/j.ijid.2022.04.029. Epub 2022 Apr 21. Int J Infect Dis. 2022. PMID: 35462038 Free PMC article.
Cited by
-
Evolution of the SARS-CoV-2 Omicron Variants: Genetic Impact on Viral Fitness.Viruses. 2024 Jan 25;16(2):184. doi: 10.3390/v16020184. Viruses. 2024. PMID: 38399960 Free PMC article. Review.
-
Biomarkers and outcomes in hospitalised patients with COVID-19: a prospective registry.BMJ Open. 2022 Dec 15;12(12):e067430. doi: 10.1136/bmjopen-2022-067430. BMJ Open. 2022. PMID: 36521904 Free PMC article.
-
Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.Open Forum Infect Dis. 2023 Apr 20;10(5):ofad216. doi: 10.1093/ofid/ofad216. eCollection 2023 May. Open Forum Infect Dis. 2023. PMID: 37152188 Free PMC article.
-
Prevalence of symptoms, comorbidities, and reinfections in individuals infected with Wild-Type SARS-CoV-2, Delta, or Omicron variants: a comparative study in western Mexico.Front Public Health. 2023 Apr 27;11:1149795. doi: 10.3389/fpubh.2023.1149795. eCollection 2023. Front Public Health. 2023. PMID: 37181688 Free PMC article.
-
Clinical characteristics, SARS-CoV-2 variants, and outcomes of adults hospitalized due to COVID-19 in Latin American countries.Clinics (Sao Paulo). 2025 Apr 23;80:100648. doi: 10.1016/j.clinsp.2025.100648. eCollection 2025. Clinics (Sao Paulo). 2025. PMID: 40273490 Free PMC article.
References
-
- “Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern”. Available at: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1..... Accessed January 13, 2022.
-
- Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature 2021;600:21–121. - PubMed
-
- “Enhancing response to Omicron SARS-CoV-2 variant.” Available at: https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-.... Accessed January 13, 2022.
-
- Wolter N, et al., “Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa,” Infectious Diseases (except HIV/AIDS), preprint, Dec. 2021. doi: 10.1101/2021.12.21.21268116.
-
- CDC. COVID data tracker. Centers for Disease Control and Prevention 2020;https://covid.cdc.gov/covid-data-trackerhttps://covid.cdc.gov/covid-data-tracker. Accessed January 13, 2022).
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous